Developing greener synthesis processes is an inescapable necessity to transform the
industrial landscape, mainly in the pharmaceutical sector, into a long-term, sustainable …

In recent years, there has been a growing interest in therapeutic peptides within the
pharmaceutical industry with more than 50 peptide drugs on the market, approximately 170 …

N, N-Dimethylformamide (DMF), N-methyl-2-pyrrolidone, and dichloromethane (DCM) are
the most widely used solvents for Fmoc solid-phase peptide synthesis (SPPS). These …

Peptides are at the cutting edge of contemporary research for new potent, selective, and
safe therapeutical agents. Their rise has reshaped the pharmaceutical landscape, providing …

Solid-phase peptide synthesis (SPPS) is generally the method of choice for the chemical
synthesis of peptides, allowing routine synthesis of virtually any type of peptide sequence …

Peptides are gaining considerable attention as potential drugs. The so-called Fmoc/tBu solid-
phase synthesis is the method of choice for the synthesis of these molecules in both …

The synthesis of peptides by amide bond formation between suitably protected amino acids
is a fundamental part of the drug discovery process. However, the required coupling and …

The quest for sustainable solvents is currently a matter of intense research and
development, as solvents significantly contribute heavily to the waste generated by chemical …

In conventional solid-phase peptide synthesis (SPPS), α-amino groups are protected with
alkoxycarbonyl groups (eg, 9-fluorenylmethoxycarbonyl [Fmoc]). However, during SPPS …

Solvents represent one of the major contributions to the environmental impact of fine‐
chemical synthesis. As a result, the use of environmentally friendly solvents in widely …